NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $4.53 +0.08 (+1.80%) Closing price 04:00 PM EasternExtended Trading$4.53 0.00 (0.00%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexeo Therapeutics Stock (NASDAQ:LXEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lexeo Therapeutics alerts:Sign Up Key Stats Today's Range$4.35▼$4.5450-Day Range$2.72▼$4.7752-Week Range$1.45▼$12.76Volume190,632 shsAverage Volume407,692 shsMarket Capitalization$150.40 millionP/E RatioN/ADividend YieldN/APrice Target$17.17Consensus RatingBuy Company Overview Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Read More Lexeo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLXEO MarketRank™: Lexeo Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 589th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.62% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted22.62% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.32 News SentimentLexeo Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lexeo Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for LXEO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,612.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LXEO Stock News HeadlinesReviewing Lexeo Therapeutics (NASDAQ:LXEO) & Cardiol Therapeutics (NASDAQ:CRDL)August 4, 2025 | americanbankingnews.comLexeo Therapeutics (NASDAQ:LXEO) Earns Outperform Rating from Analysts at OppenheimerAugust 3, 2025 | americanbankingnews.comFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $17.17August 3, 2025 | americanbankingnews.comOppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform RecommendationAugust 1, 2025 | msn.comStifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)July 29, 2025 | msn.comLexeo Therapeutics Holds 2025 Annual Stockholders MeetingJuly 25, 2025 | theglobeandmail.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - MorningstarJuly 8, 2025 | morningstar.comMSee More Headlines LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $6.58 at the beginning of the year. Since then, LXEO stock has decreased by 31.2% and is now trading at $4.53. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) issued its earnings results on Monday, May, 12th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.19. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $11.00 per share. Who are Lexeo Therapeutics' major shareholders? Lexeo Therapeutics' top institutional investors include Geode Capital Management LLC (1.74%), Privium Fund Management B.V. (0.54%), Palumbo Wealth Management LLC (0.17%) and Savant Capital LLC (0.09%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Eric Adler and Tai Sandi See. View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexeo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/12/2025Today8/08/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Price Target for Lexeo Therapeutics$17.17 High Price Target$20.00 Low Price Target$10.00 Potential Upside/Downside+288.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$98.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-85.86% Return on Assets-68.48% Debt Debt-to-Equity Ratio0.01 Current Ratio3.42 Quick Ratio3.42 Sales & Book Value Annual Sales$650 thousand Price / Sales225.50 Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book1.25Miscellaneous Outstanding Shares33,200,000Free Float31,438,000Market Cap$146.58 million OptionableNot Optionable Beta1.36 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:LXEO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.